BeiGene, Ltd. (NASDAQ:BGNE) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of $0.23 per share for the quarter.
BeiGene, Ltd. (BGNE) opened at $90.23 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 8.38 and a quick ratio of 8.38. BeiGene, Ltd. has a 52-week low of $26.43 and a 52-week high of $118.95.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/11/06/beigene-ltd-bgne-to-release-quarterly-earnings-on-wednesday.html.
In other news, Director Bros. Advisors Lp Baker purchased 176,056 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were acquired at an average price of $71.00 per share, with a total value of $12,499,976.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 19.90% of the stock is owned by insiders.
A hedge fund recently raised its stake in BeiGene stock. State Street Corp lifted its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 14.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,604 shares of the company’s stock after acquiring an additional 4,619 shares during the quarter. State Street Corp owned 0.09% of BeiGene worth $1,647,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 52.57% of the company’s stock.
Several equities analysts have issued reports on BGNE shares. Ladenburg Thalmann Financial Services started coverage on BeiGene in a research report on Monday, August 7th. They set a “buy” rating and a $81.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and set a $83.00 target price on shares of BeiGene in a research report on Monday, July 10th. Maxim Group reiterated a “buy” rating and set a $77.00 target price on shares of BeiGene in a research report on Monday, September 11th. Zacks Investment Research upgraded BeiGene from a “sell” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Tuesday, July 11th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $86.00 target price (up previously from $43.00) on shares of BeiGene in a research report on Tuesday, August 15th. Seven investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $92.50.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
What are top analysts saying about BeiGene Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BeiGene Ltd. and related companies.